Stone Research Foundation Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2020
NCT04456530
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Stone Research Foundation

Active Ingredients

Drugs in Phase 3 Trials (1)

testosterone (delatestryl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 3)

Knee Injuries (Phase 3)

Muscular Atrophy (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1